GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Radiopharm Theranostics Ltd (ASX:RAD) » Definitions » EBIT

Radiopharm Theranostics (ASX:RAD) EBIT : A$-47.17 Mil (TTM As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Radiopharm Theranostics EBIT?

Radiopharm Theranostics's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2023 was A$-24.69 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2023 was A$-47.17 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Radiopharm Theranostics's annualized ROC % for the quarter that ended in Dec. 2023 was -77.65%. Radiopharm Theranostics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -74,818.18%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Radiopharm Theranostics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -342.79%.


Radiopharm Theranostics EBIT Historical Data

The historical data trend for Radiopharm Theranostics's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Radiopharm Theranostics EBIT Chart

Radiopharm Theranostics Annual Data
Trend Jun22 Jun23
EBIT
-20.95 -34.49

Radiopharm Theranostics Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23
EBIT -8.87 -12.07 -12.01 -22.48 -24.69

Competitive Comparison of Radiopharm Theranostics's EBIT

For the Biotechnology subindustry, Radiopharm Theranostics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Radiopharm Theranostics's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Radiopharm Theranostics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Radiopharm Theranostics's EV-to-EBIT falls into.



Radiopharm Theranostics EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-47.17 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Radiopharm Theranostics  (ASX:RAD) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Radiopharm Theranostics's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

ROC % (Q: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2023 ) + Invested Capital (Q: Dec. 2023 ))/ count )
=-49.404 * ( 1 - -0.13% )/( (66.76 + 60.651)/ 2 )
=-49.4682252/63.7055
=-77.65 %

where

Note: The Operating Income data used here is two times the semi-annual (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Radiopharm Theranostics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2023  Q: Dec. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-49.38/( ( (0.068 + max(-12.991, 0)) + (0.064 + max(-8.271, 0)) )/ 2 )
=-49.38/( ( 0.068 + 0.064 )/ 2 )
=-49.38/0.066
=-74,818.18 %

where Working Capital is:

Working Capital(Q: Jun. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.105 + 0 + 0.133) - (5.119 + 0 + 8.11)
=-12.991

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(4.41 + 0 + 0.163) - (9.019 + 0 + 3.825)
=-8.271

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Radiopharm Theranostics's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2023 )
=-47.165/13.759
=-342.79 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Radiopharm Theranostics EBIT Related Terms

Thank you for viewing the detailed overview of Radiopharm Theranostics's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Radiopharm Theranostics (ASX:RAD) Business Description

Traded in Other Exchanges
Address
62 Lygon Street, Level 3, Carlton South, Melbourne, VIC, AUS, 3053
Radiopharm Theranostics Ltd is a Australian based clinical-stage radiotherapeutics company which is targeting cancer. The company has a pipeline of around four licensed platform technologies, with diagnostic and therapeutic applications in both pre-clinical and clinical stages of development. The company is engaged in research, development and commercialisation of health technologies.

Radiopharm Theranostics (ASX:RAD) Headlines

No Headlines